Protalix BioTherapeutics
PLX
45 hedge funds and large institutions have $3.53M invested in Protalix BioTherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 20 reducing their positions, and 27 closing their positions.
68% more call options, than puts
Call options by funds: $62K | Put options by funds: $37K
3.02% less ownership
Funds ownership: 7.69% → 4.67% (-3%)
32% less funds holding
Funds holding: 66 → 45 (-21)
47% less capital invested
Capital invested by funds: $6.6M → $3.53M (-$3.07M)
75% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 20
78% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$284K |
| 2 |
Renaissance Technologies
New York
|
+$159K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$77K |
| 4 |
VF
Virtu Financial
New York
|
+$45.6K |
| 5 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
+$39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$460K |
| 2 |
Goldman Sachs
New York
|
-$433K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$390K |
| 4 |
Jane Street
New York
|
-$257K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$185K |
PLX Hedge Fund Activity: Q3 2024 in Review
45 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2024, worth a combined $3.53M — down 47% from $6.6M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PLX and 6 opened new positions — a net loss of 21 holders — while 20 trimmed existing stakes and 5 added.
The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $284K. The largest seller was Millennium Management, cutting an estimated $460K.
- 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2024, down from 66 in Q2 2024.
- Funds reported $3.53M of Protalix BioTherapeutics stock for Q3 2024, down 47% quarter-over-quarter.
- 6 funds opened new Protalix BioTherapeutics positions in Q3 2024 and 27 closed out, a net change of -21 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2024 was Stratos Wealth Partners, an estimated $284K added.
- The largest Protalix BioTherapeutics seller in Q3 2024 was Millennium Management, an estimated $460K sold.
Based on aggregated 13F filings for Q3 2024.